Home  »  Hot Stocks   »  10x Genomics Inc. (TXG) upgraded Issued by Wall St...

10x Genomics Inc. (TXG) upgraded Issued by Wall Street Gurus

10x Genomics Inc. (NASDAQ:TXG) went down by -4.99% from its latest closing price compared to the recent 1-year high of $100.00. The company’s stock price has collected 4.98% of gains in the last five trading sessions. The Wall Street Journal reported on 02/17/22 that Palantir, DoorDash, Nvidia, Hasbro: What to Watch in the Stock Market Today

Is It Worth Investing in 10x Genomics Inc. (NASDAQ :TXG) Right Now?

Plus, the 36-month beta value for TXG is at 1.70. Opinions of the stock are interesting as 7 analysts out of 11 who provided ratings for 10x Genomics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $49.67, which is $4.27 above the current price. TXG currently public float of 90.75M and currently shorts hold a 8.22% ratio of that float. Today, the average trading volume of TXG was 1.37M shares.

TXG’s Market Performance

TXG stocks went up by 4.98% for the week, with a monthly jump of 23.25% and a quarterly performance of 77.30%, while its annual performance rate touched -49.01%. The volatility ratio for the week stands at 5.87% while the volatility levels for the past 30 days are set at 6.94% for 10x Genomics Inc. The simple moving average for the period of the last 20 days is 15.02% for TXG stocks with a simple moving average of 12.99% for the last 200 days.

Analysts’ Opinion of TXG

Many brokerage firms have already submitted their reports for TXG stocks, with Deutsche Bank repeating the rating for TXG by listing it as a “Buy.” The predicted price for TXG in the upcoming period, according to Deutsche Bank is $50 based on the research report published on December 14th of the previous year 2022.

Goldman, on the other hand, stated in their research note that they expect to see TXG reach a price target of $35, previously predicting the price at $55. The rating they have provided for TXG stocks is “Sell” according to the report published on August 18th, 2022.

Canaccord Genuity gave a rating of “Buy” to TXG, setting the target price at $55 in the report published on July 25th of the previous year.

TXG Trading at 20.78% from the 50-Day Moving Average

After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.47% of loss for the given period.

Volatility was left at 6.94%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares surge +24.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.72% upper at present.

During the last 5 trading sessions, TXG rose by +4.98%, which changed the moving average for the period of 200-days by -38.11% in comparison to the 20-day moving average, which settled at $40.04. In addition, 10x Genomics Inc. saw 24.95% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 2,676 shares at the price of $34.07 back on Nov 22. After this action, Saxonov Serge now owns 974,926 shares of 10x Genomics Inc., valued at $91,158 using the latest closing price.

McAnear Justin J., the Chief Financial Officer of 10x Genomics Inc., sale 1,626 shares at $34.07 during a trade that took place back on Nov 22, which means that McAnear Justin J. is holding 76,764 shares at $55,392 based on the most recent closing price.

Stock Fundamentals for TXG

Current profitability levels for the company are sitting at:

  • -10.79 for the present operating margin
  • +84.89 for the gross margin

The net margin for 10x Genomics Inc. stands at -11.87. Equity return is now at value -21.00, with -16.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 6.77.

Can PepsiCo Inc. (PEP) Remain Competitive?

PepsiCo Inc. (NASDAQ:PEP) went down by -0.93% from its latest closing price compared to the recent 1-year high of $186.84. The company’s stock price has